REGENXBIO Inc. financial data

Symbol
RGNX on Nasdaq
Location
Rockville, MD
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 286% % -9.3%
Debt-to-equity 127% % 83%
Return On Equity -78% % -11%
Return On Assets -34% % 17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50,623,086 shares 2.2%
Common Stock, Shares, Outstanding 50,619,000 shares 2.2%
Entity Public Float $536,344,977 USD -33%
Common Stock, Value, Issued $5,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 51,689,000 shares 1.8%
Weighted Average Number of Shares Outstanding, Diluted 51,689,000 shares 1.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $161,318,000 USD 91%
Research and Development Expense $219,068,000 USD 2.5%
General and Administrative Expense $80,534,000 USD 6.5%
Costs and Expenses $316,248,000 USD -4.2%
Operating Income (Loss) $154,930,000 USD 37%
Nonoperating Income (Expense) $22,985,000 USD -432%
Net Income (Loss) Attributable to Parent $177,915,000 USD 25%
Earnings Per Share, Basic -3 USD/shares 31%
Earnings Per Share, Diluted -3 USD/shares 31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $58,802,000 USD 3.9%
Marketable Securities, Current $215,403,000 USD 8.3%
Cash, Cash Equivalents, and Short-term Investments $302,000,000 USD 8.4%
Accounts Receivable, after Allowance for Credit Loss, Current $25,347,000 USD 7.4%
Other Assets, Current $19,472,000 USD 21%
Assets, Current $331,967,000 USD 5.9%
Property, Plant and Equipment, Net $107,515,000 USD -11%
Operating Lease, Right-of-Use Asset $48,820,000 USD -12%
Other Assets, Noncurrent $4,268,000 USD -1.5%
Assets $525,203,000 USD 1.2%
Accounts Payable, Current $22,266,000 USD 14%
Employee-related Liabilities, Current $15,076,000 USD 5.2%
Contract with Customer, Liability, Current $13,195,000 USD 9063%
Liabilities, Current $124,568,000 USD 21%
Contract with Customer, Liability, Noncurrent $21,186,000 USD
Operating Lease, Liability, Noncurrent $67,433,000 USD -12%
Other Liabilities, Noncurrent $648,000 USD -82%
Liabilities $363,751,000 USD 67%
Accumulated Other Comprehensive Income (Loss), Net of Tax $652,000 USD -12%
Retained Earnings (Accumulated Deficit) $1,058,878,000 USD -20%
Stockholders' Equity Attributable to Parent $161,452,000 USD -46%
Liabilities and Equity $525,203,000 USD 1.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $33,629,000 USD
Net Cash Provided by (Used in) Financing Activities $5,794,000 USD -105%
Net Cash Provided by (Used in) Investing Activities $44,743,000 USD 239%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 50,619,000 shares 2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $72,578,000 USD -7.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,832,000 USD 3.7%
Deferred Tax Assets, Valuation Allowance $338,352,000 USD 21%
Deferred Tax Assets, Gross $377,059,000 USD 16%
Operating Lease, Liability $82,033,000 USD -8.1%
Payments to Acquire Property, Plant, and Equipment $1,024,000 USD 84%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $177,985,000 USD 23%
Lessee, Operating Lease, Liability, to be Paid $110,213,000 USD -9.9%
Property, Plant and Equipment, Gross $191,054,000 USD 0.61%
Operating Lease, Liability, Current $9,073,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $12,885,000 USD 1.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,345,000 USD 3.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $28,180,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $10,003,000 USD -21%
Deferred Tax Assets, Operating Loss Carryforwards $105,468,000 USD 70%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $100,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,940,000 USD -21%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $38,707,000 USD -11%
Share-based Payment Arrangement, Expense $35,730,000 USD -4.1%
Interest Expense $5,409,000 USD -62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%